result confirm insul durabl across
segment updat materi posit off-set
quarter bd report revenu cc vs mse
estim compani withdrew guidanc
expect bd estim impact bp global
headwind adjust factor underli organ growth
better consensu reflect momentum stabil major
headwind china discuss note us
experienc slight net tailwind bp relat increas demand
critic care devic well initi contribut bd covid-
test adjust ep mse primarili
driven higher oper margin vs mse due lower
phase durabl evid detail review segment see phase
three key quarter includ diagnost contribut time
process updat alari issu potenti upsid tie prospect
confirm consist expect see
analysi bd began clinic test poc test
well discuss fda pre-eua file concurr bd
ramp product capac object produc
million per week expect play signific role poc
antigen screen test offer rel accur easi use solut
ambulatori set given small size rapid result
expect could adapt pharmaci workplac drive-
test site similar abbott id-now today bd
system place vs id-now system abbott
updat model reflect potenti financi contribut
await accuraci confirm approv base
case assumpt said
model reflect bd max
biomedom serolog
timelin push alari focu sinc follow
fda notif februari requir submiss comprehens
medic technolog unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
address pump remedi deep dive see bd issu
first thought math bd/baxter dynam
addit receiv letter compani longer expect
submit file due delay human factor test
anticip updat time earn bd abil sell
medic necess known tailwind assum reduc
expect hit pump recal said
compani state pump benefit april like slow
reflect model futur offset much tie
hospit pandem demand may sentiment
vaccin contribut modest bd process ramp
product inject syring needl prepar potenti
larg scale vaccin campaign potenti surg demand
begin see earli stockpil vaccin
pre-filled devic see rang assum unit
translat annual opportun bp corpor
growth realiti consid market share see vaccin
worth ten million given margin profit opportun
modest
reconcil dynam bd withdrew guidanc provid detail
estim impact preliminari april revenu
drive net neg impact guidanc impli low-teen declin
april improv across quarter assum moder declin
remaind anticip quarter sever
impact normal revenu line recoveri
model model underli growth vs prior
adjust om declin primarili reflect revenu
loss impact higher gross margin profil segment
corpor averag base compani guidanc net lower ep
declin exhibit key model chang
alter landscap thesi support light
dynam situat highlight bd key phase recoveri stori
investor look rel insul posit off-set stori medic
devic beyond defens insul confirm result believ
diagnost bd max serolog test could posit
offset next sever quarter diagnost test becom
meaning annual contributor core busi perpetu exist
thesi center durabl core busi model sustain growth
profil posit offset present balanc risk/reward profil
current valuat ebitda pt remain equal-weight
path less clear rel resili
price target base multipl base case
ebitda one turn larg cap peer set organ growth sustain continu
new product ramp partial off-set china pump nois prior
stabil cost program gain traction bard synergi integr track
sustain growth prole
potenti double-digit earn growth
head last year deal
model bard remain meaning driver
margin improv lever growth
acceler support em penetr
aggress action cost may
expect rel resili covid
view descript risk reward theme
thomson reuter morgan stanley research morgan stanley institut equiti divis probabl
bull base bear case scenario play estim impli volatil data option market
may gure approxim risk-neutr probabl stock reach beyond scenario
price either three-month one-year time view explan option probabl methodolog
resili covid exce expect
sale acceler bard drive
addit growth high singl digit
bd deliv synergi materi
forecast ahead schedul
manufactur reloc erp
implement yield greater expect
organ growth sustain becom
evid new product ramp
integr track bd/bard
covid impact greater expect bard
integr take longer anticip
organ growth slow due
addit eu auster poor pipelin
buyback poor execut cost
initi addit price pressur
multipl contract low end
em repres around sale may
drive growth acceler
protabl doubl digit growth like
requir exceed guidanc
china india
view explan region hierarchi
research highest favor quintil
swift fda resolut result minim
impact result
faster expect btk approv
synergi realiz greater ahead
integr lag promis synergi fail
prolong fda process resolut
competit pressur em mount
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
deliveri line expect perform impact
distributor inventori reduct relat china tender process around intima ii
us net tailwind driven surg demand distributor stock
partial off-set lower routin elect procedur acut care lower
util non-acut set
manag vs mse reflect limit instal alari
pump anticip sale respons relat demand sold
medic necess expect month april unlik
continu pace beyond april
pharma system vs mse grew cc continu demand
pre-fil syring aid time shipment
diagnost vs mse cc bp impact flu
relat test
preanalyt system vs mse normal grew cc
bp impact wingset growth develop market favor comp
peripher vs mse grew cc bp impact
broad base expans venovo wavelinq covera addit within
peripher bd saw improv y/i declin dcb-relat revenu driven
continu commerci dcb japan sale relat two new product
launch us addit compani provid time updat btk
note complet submiss addit data includ number addit
clinic studies/data set lutonix btk file continu fda review
china pressur expect major relat headwind
china driven stay-at home measur lower hospit util declin elect
procedur well fewer routin lab test relat specimen collect china
revenu y/i pt attribut
april neg impact continu acut china surgeri
revenu track expect segment subject
hospit util md ucc
area weak larg expect bioscienc vs mse
normal cc bp impact reduc demand
instrument reagent research lab activ slow due surgeri
vs normal cc bp impact driven
impact demand elect procedur us china
million except ep
million
million
incom cont op
net incom common
current portion net invest sales-typ leas
net invest sales-typ leas less
payabl accru expens
defer incom tax
commit conting
depreci amort
net work capit
oper
sale purchas invest
proce discontinu oper
invest
chang short term debt
proce repay long term debt
payment debt
repurchas common
issuanc common stock
financ
net cash provid oper activ
net cash use invest activ
net cash use financ activ
effect exchang rate chang
begin period balanc
end period balanc
